# Script CJC-1295 — Can a doctor write a prescription for CJC-1295? > A plain-language reading of the CJC-1295 prescribing record: FDA status, the 503A compounding pathway, the 2024 PCAC reviews, WADA S2, and the published Phase 1 research. Short answer: not in 2026. The longer answer involves three FDA decisions, one halted Phase 2 trial, and one Joe Rogan announcement. ## The short version CJC-1295 is a synthetic version of a hormone the body already makes — growth-hormone-releasing hormone, or GHRH — but engineered to last days instead of minutes. One modification (called DAC) tethers the peptide to a blood protein called albumin, giving it a half-life of roughly six to eight days in people [3]. That means a single dose keeps growth hormone (GH) and a downstream signal called IGF-1 elevated for over a week. The compound has never been approved by the FDA for any human use [14]. A small Phase 1 study in healthy adults published in 2006 is the only peer-reviewed human trial [2]. A larger Phase 2 trial was halted the same year and its results were never published [8]. As of 2026, compounding pharmacies operating under 503A rules have no clear legal path to fill a CJC-1295 prescription [20]. For the fuller picture — what it does in the body, what people report, and what the regulatory record actually shows — the pages below are where to start. See also [what people report about effects and side effects](/effects). ## What people are asking The phrase "script CJC-1295" is what someone types after asking a friend out loud whether a doctor can prescribe a particular peptide. It is a small, specific question, and it has a small, specific answer. CJC-1295 has never been approved by the U.S. Food and Drug Administration for any human indication [14]. The Drugs@FDA database returns no result for the compound. The original sponsor — ConjuChem Biotechnologies — halted its development program in October 2006 after a participant death during a Phase 2 trial in HIV-associated visceral adiposity, and no New Drug Application has been filed by any sponsor since [8][14]. This site reads the regulatory record carefully and reports what it says. It does not prescribe. It does not refer. It does not sell. ## Why "prescription" is the wrong frame A licensed U.S. physician can write a prescription for any compound they judge appropriate. The harder question is what a pharmacy can lawfully dispense in response. For an FDA-approved drug, the pathway is simple — the manufacturer ships a labeled product, and a pharmacy fills the prescription. For an unapproved compound, the only legal route is **compounding** under Section 503A of the Federal Food, Drug, and Cosmetic Act, and 503A has three statutory criteria. CJC-1295 fails all three: there is no USP/NF monograph, it is not a component of an FDA-approved drug, and it is not on the FDA 503A bulks list [20]. For a brief window — between the 2023 placement of CJC-1295 in interim Category 2 and the September 27, 2024 removal of that placement — the regulatory status was at least under active categorization [16]. As of 2026, even that scaffold is gone: the January 7, 2025 final interim guidance closed the Category 1/2/3 system to new nominations [18]. ## What the science actually shows Underneath the regulatory record there is a small, coherent body of pharmacology. CJC-1295 is a 30-amino-acid analog of growth hormone-releasing hormone (GHRH), built on the first 29 residues of human GHRH with four protective amino acid substitutions and a C-terminal maleimide group that covalently tethers the peptide to circulating serum albumin. The tether is the defining feature — it extends the plasma half-life from minutes (native GHRH) to roughly six to eight days in healthy adults [3]. The only published Phase 1 paper, Teichman et al. 2006, dosed healthy adults at 30, 60, 125, or 250 μg/kg as a single subcutaneous injection and reported a two- to ten-fold elevation in mean plasma growth hormone (GH) for at least six days, with IGF-1 elevated 1.5- to three-fold for nine to eleven days [2][3]. That paper remains the only peer-reviewed Phase 1 trial of CJC-1295 in the endocrinology literature. There is no Phase 3 evidence. There is no completed Phase 2 outcome paper. ## How to read this site This is an editorial project. It summarizes peer-reviewed studies, FDA briefing documents, and the public regulatory record on a single compound. The **research** page walks through the published mechanism and the available human and animal data. The **dosage** page reports the dose ranges that were administered in published research — not as a prescribing guide, but as a literal record of what investigators gave to study animals and Phase 1 volunteers. The **effects** page draws on the corpus of community-reported signals and the evidence-based safety cautions, both honestly labeled. The **FAQ** answers the questions that bring most readers here. The **references** page lists every primary source. This site is an independent editorial reading of publicly available research. It does not prescribe, refer, manufacture, sell, or distribute any product. --- An independent editorial reading of publicly available research — not a clinic, not a prescriber, not a vendor.